Roche just heralded a great set of placebo comparisons for their new flu drug — too bad it flopped against generic Tamiflu
Genentech just rolled out some of the hard data around its Phase III CAPSTONE-2 trial for their new flu medicine baloxavir marboxil, and it doesn’t look good.
Once you dig through the bonny remarks and keep going on to the statistically significant placebo comparisons, the pharma giant throws in a major snafu. Their flu drug failed to prove significantly better than Tamiflu in a head-to-head comparison on the time it took to reduce symptoms of the flu. And that’s the money shot.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
